Convalife Pharmaceuticals, a Shanghai-based clinical pharmaceutical company, and Divamics Inc., a Suzhou-headquartered biopharmaceutical firm specializing in artificial intelligence (AI), quantum mechanics, and molecular simulation algorithms, have announced a strategic partnership agreement. This collaboration aims to revolutionize the drug discovery process by combining cutting-edge AI capabilities with advanced molecular dynamics simulation.
Under the terms of the agreement, both companies will jointly develop an innovative drug molecular design platform, with a focus on multi-scale molecular dynamics simulation at its core. Convalife will integrate Divamics’ sophisticated core algorithm platform system into its own Right 6D new drug development strategy. This synergy is expected to significantly expedite the new drug development process by harnessing Divamics’ next-generation AI and its state-of-the-art drug calculation and design platform, which incorporates multi-scale molecular dynamics.- Flcube.com
